Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Eur J Haematol. 2022 Nov;109(5):590-592. doi: 10.1111/ejh.13837. Epub 2022 Aug 5.
B-cell prolymphocytic leukaemia (B-PLL) is an aggressive B-cell lymphoproliferative disease with few clinically proven targeted treatments. Due to the rarity of the condition, there is a paucity of clinical trial data and none that involve targeted inhibitors. We present a unique case of relapsed refractory B-PLL treated to a sustained minimal residual disease-negative remission with venetoclax monotherapy, to add to the current evidence base and rationale for future studies using BCL-2 inhibitors in B-PLL.
B 细胞前淋巴细胞白血病（B-PLL）是一种侵袭性 B 细胞淋巴增生性疾病，目前仅有少数经临床验证的靶向治疗方法。由于该病较为罕见，因此临床试验数据很少，且没有涉及靶向抑制剂的试验。我们报告了一例复发性难治性 B-PLL 病例，该患者接受维奈托克单药治疗后达到持续微小残留病灶阴性缓解，为目前的循证医学证据添加了新内容，并为未来在 B-PLL 中使用 BCL-2 抑制剂的研究提供了理论依据。
